Fig. 7

Antitumor effect of MGCN in vivo. A. Appearance of tumor after therapy. B16-F10 subcutaneous model was first established and C57BL/6 mice were randomized into five groups with different treatments (n = 5): (1) NS; (2) HPI; (3) HPI/PEI-FPBA/HSP70-shRNA - Light; (4) HPI/PEI-FPBA/Con-shRNA + Light; and (5) HPI/PEI-FPBA/HSP70-shRNA + Light. B. Tumor growth curves of mice. Tumor volumes were monitored and individual tumor volumes were plotted. C. Tumor volume-time curves. **P < 0.01, ***P < 0.001. D. Average tumor weight of tumor-bearing mice. After different treatments, the subcutaneous tumors were removed and weighed. E. Body weight change curves of mice. Weight was determined every 2 days. F. TUNEL staining in tissue sections from the tumor. Positive cells were stained by FITC (green) and nuclei were stained by DAPI (blue). The scale bar represented 50 μm. G. Histological examination of H&E staining of tumor sections. The scale bar represented 50 μm. H. Immunohistochemical localization of HSP70 protein. The scale bar represented 50 μm. The positive expression color was tan